 This is a descriptive study in intestinal failure patients with catheter-related blood stream infections CRBSI with fungal organisms. At present, the recommendation of the Infectious Disease Society of America IDSA is to remove all catheters with fungal infections and treat systemically for 14 days after the last positive culture 2. However, in intestinal failure patients who have limited IV access, removal of a line infected with Candida albicans, although recommended, might significantly reduce intravenous access and create a life threatening situation. Thus, the purpose of this study is to evaluate the use of antifungal lock therapy with liposomal amphotericin B Ambisome in combination with systemic antifungal therapy in patients with fungal CRBSI, whose catheter has not been removed because of the continuing critical need for central line access. The research methods are as follows: 